Buspirone
Treatment for Anxiety Disorder
Typical Dosage: 15-60mg daily in divided doses
Effectiveness
60%
Safety Score
65%
Clinical Trials
16
Participants
10K
Comparative Safety Scale(Higher is safer)
Cyanide☠️
Meth💀
Cigarettes🚬
Chemo☢️
Alcohol🍺
Morphine💊
Antibiotics💉
Tylenol💊
Exercise🏃
Water💧
65
DangerousModerateSafe
Treatment Details
Dosage Range
15-60mg daily in divided doses
Time to Effect
2-4 weeks
Treatment Duration
Long-term, as needed
Evidence Quality
MODERATENumber Needed to Treat (NNT)
9(Treat 9 patients to see 1 additional successful outcome)
Confidence Score
80%confidence in effectiveness data
Health Economics
Annual Cost of Care
Drug Cost:$200
Monitoring:$150
Side Effect Mgmt:$50
Total Annual:$400
Cost-Effectiveness Analysis
Cost-Effectiveness Rating
GOODICER
$38,000/QALY
QALYs Gained
0.15
Outcome-Based Costs
Cost per Responder
$889
Cost per Remission
$2,000
Comparison vs No Treatment
Cost Difference
+$400/year
More expensive
QALY Difference
+0.15 QALYs
Better outcomes
Dominance
No dominance
Buspirone Outcomes
for Anxiety Disorder
Efficacy Outcomes
Overall Effectiveness
+60%
Response Rate
+45%
Remission Rate
+20%
Common Side Effects
Dizziness
+10%
Nausea
+8%
Headache
+6%
Sources:
Active Clinical Trials
3 active trials recruiting for Buspirone in Anxiety Disorder
Phase Ⅲ Clinical Trial of Buagafuran Capsules in the Treatment of GAD
NCT06243614RECRUITINGPHASE3
410 participants
INTERVENTIONAL
Beijing, China
Started: Jul 24, 2023
Evaluating Buspirone to Treat Opioid Withdrawal
NCT05511909ACTIVE NOT RECRUITINGPHASE2
100 participants
INTERVENTIONAL
Baltimore, United States
Started: Dec 15, 2022
Measurement of the Hippocampal Theta Rhythm From the Outer Ear Canal
NCT03954483RECRUITINGNA
42 participants
INTERVENTIONAL
Winnipeg, Canada
Started: Oct 16, 2023
Completed Clinical Trials
6 completed trials for Buspirone in Anxiety Disorder
An Open-Label Trial of Buspirone for the Treatment of Anxiety in Youth With Autism Spectrum Disorders
NCT01850355COMPLETEDNA
9 participants
INTERVENTIONAL
Boston, United States
Started: Jul 1, 2013
Buspirone Treatment of Anxiety in Williams Syndrome
NCT04807517COMPLETEDPHASE4
20 participants
INTERVENTIONAL
Lexington, United States
Started: Aug 1, 2021
Buspirone in Parkinson's Disease
NCT02803749COMPLETEDPHASE2
21 participants
INTERVENTIONAL
Rochester, United States
Started: Oct 1, 2016
Improving Driving in Young People With Autism Spectrum Disorders
NCT03538431COMPLETEDPHASE4
26 participants
INTERVENTIONAL
Boston, United States
Started: Oct 31, 2018
Evaluate the Quality of Life and Treatment of Anxiety Symptoms of Buspirone in Patients With Depression Disorders(BASIS)
NCT04770454COMPLETED
200 participants
OBSERVATIONAL
Seoul, South Korea
Started: Feb 8, 2021
Efficacy of Online CBT for GAD Compared to Pharmaceutical Interventions
NCT04478526COMPLETEDNA
115 participants
INTERVENTIONAL
Kingston, Canada
Started: Apr 29, 2020